Using AMG900 to Treat Breast Cancer
Richard S. Finn, MD, discusses the aurora kinase inhibitor AMG900.
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the aurora kinase inhibitor AMG900.
Clinical Pearls
- AMG900 is a small molecule inhibitor of aurora kinases, which are proteins that are involved in maintaining DNA integrity and controlling DNA replication
- AMG900 has been evaluated in breast cancer models to try to determine which group of patients will benefit
- Results of an AMG900 trial showed that patients with p53 mutation may have a potential benefit with the agent
- p53 mutations are common throughout all the molecular subtypes of breast cancer but triple-negative breast cancer (TNBC) shows a higher frequency of these mutations
- This early preclinical work suggests that p53 mutations may act as a biomarker for selecting patients who will benefit from AMG900
- AMG900 is now in a phase I study that includes patients with TNBC and a biomarker component will be included in the study to help researchers get a better understanding of how the drug is working
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
